Docetaxel resistance in castration-resistant prostate cancer: transcriptomic determinants and the effect of inhibiting Wnt/β-catenin signaling by XAV939
E Pudova, A Kobelyatskaya, I Katunina… - International Journal of …, 2022 - mdpi.com
Castration-resistant prostate cancer (CRPC) is a common form of prostate cancer in which
docetaxel-based chemotherapy is used as the first line. The present study is devoted to the …
docetaxel-based chemotherapy is used as the first line. The present study is devoted to the …